XLON
IBAI
Market cap2mUSD
Jun 20, Last price
0.72GBP
Name
IQ-AI Ltd
Chart & Performance
P/E
—
P/S
2.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.20%
Rev. gr., 5y
22.87%
Revenues
750k
+23.09%
Net income
-327k
L-47.56%
CFO
-136k
L+40.62%
Dividend
Apr 06, 20110.8 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Saint Helier, Jersey, IQ-AI Limited is a technology firm that develops sophisticated software solutions for the healthcare sector, with operations extending to the United States. Its diverse product suite supports medical imaging and diagnostics. Key offerings include IB Clinic, a set of post-processing plug-ins designed to enhance existing image visualization platforms; IB Rad Tech, an engine for streamlining custom clinical workflows; and IB Neuro, which processes MR data to create detailed parametric perfusion maps. The company also provides IB Delta Suite for essential radiology functions such as image co-registration and subtraction. Specialized tools further include IB DCE for analyzing T1-weighted images to derive perfusion and permeability parameters, and IB Diffusion for generating various parameter maps from MR diffusion-weighted data, such as apparent diffusion coefficients and IVIM. Additionally, IB StoneChecker assists clinical decision-making related to kidney stones. Beyond these software innovations, IQ-AI Limited offers valuable consulting services. The company adopted its current name in October 2018, having previously operated as Flying Brands Limited.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||